Cargando…

Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States

BACKGROUND: The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM), was approved in 2015 in the United States. Information on the uptake, user characteristics, and outcomes of follow-on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rai, Ashish, Nam, Young Hee, Mendelsohn, Aaron B, Marshall, James, McDermott, Cara L, Toh, Sengwee, Lockhart, Catherine M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387990/ https://www.ncbi.nlm.nih.gov/pubmed/37404073 http://dx.doi.org/10.18553/jmcp.2023.29.7.842

Ejemplares similares

Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population
por: Mendelsohn, Aaron B., et al.
Publicado: (2020)

Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product
por: Mendelsohn, Aaron B., et al.
Publicado: (2021)

Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study
por: Chang, Chia-Hsuin, et al.
Publicado: (2011)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
por: Trujillo, Jennifer M., et al.
Publicado: (2018)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
por: Roussel, Ronan, et al.
Publicado: (2017)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
por: Davies, Melanie J., et al.
Publicado: (2017)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
por: Bolli, Geremia B., et al.
Publicado: (2020)

Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model
por: Luna, Ernesto, et al.
Publicado: (2018)

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials
por: Danne, Thomas, et al.
Publicado: (2020)

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin
por: Lim, Soo, et al.
Publicado: (2014)

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
por: Frias, Juan P., et al.
Publicado: (2018)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects
por: Crutchlow, Michael F., et al.
Publicado: (2017)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program
por: Goldman, Jennifer D., et al.
Publicado: (2018)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients
por: Harreiter, Jürgen, et al.
Publicado: (2017)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
por: Huang, Ting-Ying, et al.
Publicado: (2022)

Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis
por: McDermott, Cara L, et al.
Publicado: (2018)

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
por: Hanefeld, Markolf, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rs3ktvi5qdtlrl95vl5ikdbifm